Clinical Trial Update: A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating azacitidine in myelodysplastic syndrome associated with systemic autoimmune and inflammatory disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome
• Systemic Autoimmune Diseases

Drugs mentioned

• AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: MDS, Systemic Autoimmune Diseases | Phase 2 | Status: COMPLETED